5 Best Performing Dow Stocks So Far in 2026

In this article, we will take a look at the 5 Best Performing Dow Stocks So Far in 2026. For a deeper discussion and an extended list, please see the 10 Best Performing Dow Stocks So Far in 2026. 

5. Johnson & Johnson (NYSE:JNJ)

Year-to-date return as of April 16: 13.11%

On April 14, 2026, Reuters reported that Johnson & Johnson (NYSE:JNJ) topped first-quarter earnings projections and raised its full-year forecast. The firm reported revenue of $24.1 billion, above forecasts of $23.6 billion. The adjusted earnings per share were $2.70 as compared to $2.66 projected. Strong demand for Darzalex and Tremfya offset a significant dip in Stelara sales.

Stelara sales fell over 60% year on year to $656 million when the patent expired. Tremfya’s quarterly sales were $1.6 billion, beating the $1.2 billion prediction. Darzalex delivered $4 billion, exceeding the $3.4 billion expectations. According to CFO Joseph Wolk, patients have shifted away from biosimilars in favor of other treatments.

The corporation announced early success with Icotyde, pointing out approximately 1,500 prescriptions within weeks of launch. Johnson & Johnson (NYSE:JNJ) raised its sales forecast for 2026 to a midpoint of $100.8 billion and its adjusted EPS guidance to $11.55. Medical device sales rose by 7.7% to $8.6 billion, matching expectations.

Johnson & Johnson (NYSE:JNJ) is a holding corporation that researches, develops, manufactures, and sells healthcare products. It operates through two segments: Innovative Medicine and MedTech.